stockrowGrifols, S.A.
GRFSHealthcare Drug Manufacturers General
Grifols, S.A.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 billion, up 9.07% from fiscal 2024.
- Revenue
- +9.37%
- EPS
- +59.8%
- Free cash flow
- +4.11%
- Total debt
- −6.08%
Quarter to September 2026, against a year earlier
Follow GRFS
Alert me
Grifols, S.A. (GRFS) Price to free cash flow
As of 6 November 2026, Grifols, S.A. (GRFS) trades at a price to free cash flow of 7.6×. Over the past ten years it has ranged from 0.0× (September 2024) to 884× (February 2023); the current reading is higher than 28% of that period. That is below the Drug Manufacturers General industry median of 21.7× and below the Healthcare sector median of 20.5×.
Price to free cash flow, daily
Embed this chart
Annual newest first
| Period | Price to free cash flow | Change |
|---|---|---|
| FY2025 | 9.9× | (46.12%) |
| FY2024 | 18.3× | — |
| FY2023 | 0.0× | — |
| FY2022 | 723× | 12,063.16% |
| FY2022 | 5.9× | 3.65% |
| FY2021 | 5.7× | (73.00%) |
| FY2021 | 21.2× | 2.77% |
| FY2020 | 20.7× | (48.19%) |
| FY2020 | 39.9× | 1.33% |
| FY2019 | 39.3× | 59.58% |
Quarterly newest first
| Period | Price to free cash flow | Change |
|---|---|---|
| Sep 2026 | 6.6× | (26.82%) |
| Mar 2026 | 9.1× | (8.04%) |
| Dec 2025 | 9.9× | (29.83%) |
| Sep 2025 | 14.0× | (41.29%) |
| 29 more quarters | Free account |
Against its own ten years
Price to free cash flow against peers
| Company | Price to free cash flow |
|---|---|
| NSRX Nasus Pharma Ltd. compare | n/m |
| OGN Organon & Co. compare | 6.3× |
| AMRN Amarin Corporation PLC compare | 6.5× |
| SNY Sanofi compare | 6.7× |
| GRFS Grifols, S.A. | 7.6× |
| GSK GSK PLC Sponsored ADR compare | 11.4× |
| BMY Bristol Myers Squibb Company compare | 13.7× |
| BIIB Biogen Inc. compare | 21.7× |
| NVO Novo Nordisk A/S compare | 25.8× |
| Drug Manufacturers General industry median | 21.7× |
| Healthcare sector median | 20.5× |
| Market median | 14.0× |
What Price to free cash flow is
Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.
Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))
More on GRFS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement